Company intelligence / Profile preview

AllerQuest LLC

Plainville, Connecticut, United Statesallerquest.com ↗

Ownership: Private
Employees: ~16
Development stage: Commercial

Overview

AllerQuest developed PRE-PEN, the only FDA-approved diagnostic skin test for the evaluation of penicillin allergy. The product was acquired by ALK-Abelló in January 2024.

Therapeutic areas: Immunology
Modalities: Skin test reagents, specifically benzylpenicilloyl polylysine injection
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

penicillin skin antigen test

Commercial

Indications: Penicillin allergy

Partnerships

ALK-Abelló (distribution partner for over 14 years before acquisition)

Beyond the preview

Go deeper on AllerQuest LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AllerQuest LLC.

Explore the full profile